For release content, please refer to the attachment.
Recommended Reading
-
Pelabresib 144-week Phase III MANIFEST-2 data show sustained clinical effects in longest follow-up from a combination trial in first-line JAKi-naïve myelofibrosisKISQALI® six-year NATALEE analysis...
Read More -
Cosentyx® (secukinumab) doubled sustained remission rates and demonstrated steroid-sparing effects vs placebo in Phase III trial¹Approval marks 11th US indication for Cosentyx, building on its...
Read More